When the Rules Decide Who Buys
Selling into Regulated Markets | Founders Hive – Go-to-Market Series, Part 6
Your customer loves the product. The pilot works. The head of department wants to roll it out. And then the deal stalls. Not because your technology failed—but because nobody can answer three questions: Who pays? Who is allowed to buy? And what must be approved first?
For founders selling to hospitals, public institutions, pharmaceutical companies or AI-intensive businesses, the route to revenue is rarely a straight line from demo to contract. It runs through reimbursement rules, procurement procedures, compliance teams and trusted professionals. The best founders do not treat those obstacles as paperwork to tackle after closing. They design their go-to-market strategy around them.
Four Swiss start-ups show what that looks like: heyPatient, macu4, LatticeFlow AI and Risklick. Their experiences offer a practical framework for selling when the rules are part of the market.
Three numbers that can change your sales plan
CHF 150,000 / CHF 250,000 — Under the Swiss intercantonal procurement framework (IVöB), these are the key thresholds for standard supplies and services outside the international-treaty regime: direct awards below CHF 150,000; invitation procedures from CHF 150,000 up to below CHF 250,000; normally open or selective procedures from CHF 250,000. Federal and special-sector rules differ.
2 December 2027 / 2 August 2028 — The deferred application dates for key EU AI Act high-risk-system requirements: Annex III systems first, and certain AI systems embedded in regulated products later. Other AI Act provisions are already applicable.
12 months; 10–25 experts — The time and specialist effort a clinical-trial protocol may require, according to Risklick founder Dr Poorya Amini. This is the founder’s estimate, not an independently established industry average.
1. First find the money—not just the user
“If something in health care is not reimbursed, why should they pay for that service?” That question shaped the strategy of heyPatient, founded by Regula and Matthias Spühler to make hospital patient journeys easier to navigate. A clinician may immediately see the value of a digital solution yet have no budget to purchase it.
Consider Swiss acute inpatient care. Under SwissDRG, hospitals generally receive case-based payments. If a new digital tool is not separately reimbursable, it must often justify itself inside an existing budget: less administrative work, more efficient processes, better patient experience or another measurable benefit. Reimbursement arrangements vary by setting and product, so founders need to test the precise payment pathway rather than assume one.
For macu4, the Swiss developer of 3D-printed prosthetic and orthotic solutions, a promising market can unravel when payment or distribution assumptions prove wrong. “Either there is no reimbursement coming, or the partners do not want to implement you in the portfolio, and then you need to adapt,” says CEO Myriam Lingg.
The implication is uncomfortable but valuable: product–market fit is not enough. In regulated markets, you also need product–budget fit.
THE FOUNDER PLAYBOOK
- Draw a buying map with four distinct roles: user, clinical or technical champion, economic buyer and authorised signatory. One person may hold several roles.
- Identify the actual payment source: reimbursement tariff, insurer, procurement budget, operating expenditure or approved innovation funding.
- Quantify the value proposition for the organisation carrying the cost—not only for the professional using the product.
2. Understand the buying procedure before forecasting the deal
A public-sector customer may want your solution and still be unable to sign a contract directly. For heyPatient, larger institutions often involve formal tenders, while smaller buyers can follow different purchasing routes. The decisive question is not simply “Do they want it?” but “What procedure does the institution have to follow?”
Under IVöB 2019, standard supplies and services outside the treaty-covered regime may normally be directly awarded only below CHF 150,000. Invitation procedures cover the next band, while open or selective procedures are generally required from CHF 250,000. Contract valuation considers the anticipated total commitment, including options and extensions, excluding VAT; artificial splitting to evade thresholds is not permitted. A four-year software licence at CHF 60,000 per year, for example, represents CHF 240,000 before any additional options.
These figures are not a universal Swiss rule: federal buyers have their own thresholds, some purchases follow special regimes, and exceptions require case-specific legal assessment. A hospital’s legal form and purchasing status also matter.
The opportunity is real but underused. A 2026 ZEW policy brief covering 4,260 young German firms found that 16.3% had applied for a public contract and 10.4% had won one. The research suggests that evaluation criteria beyond price—such as quality or innovation—can improve access for innovative firms. This is German evidence, not a Swiss market estimate.
A procurement officer needs an auditable decision. That means your evidence must travel beyond the enthusiastic pilot team: reference cases, measurable outcomes, cybersecurity documentation, data-protection assurances and procurement-ready pricing.
THE FOUNDER PLAYBOOK
- Ask procurement early: Are you subject to BöB or IVöB, and which procedure applies to the expected full contract value?
- Monitor simap.ch for relevant tenders, award notices and the language buyers use in specifications.
- Build a tender evidence folder before the request for proposals arrives; do not assume a successful pilot guarantees an award.
3. Sell the business case, not the regulatory deadline
A new rule can turn a neglected risk into an urgent budget line. That is part of the opportunity for LatticeFlow AI, which helps organisations assess and govern AI systems. Together with ETH Zurich and INSAIT, the company introduced COMPL-AI in October 2024, an open-source evaluation framework connecting technical tests with EU AI Act requirements for large language models.
But regulation is not a stable launch calendar. The EU’s 2026 AI Omnibus moved the application of important high-risk obligations to 2 December 2027 for Annex III systems and 2 August 2028 for certain product-related systems. Other provisions—including parts of the AI Act already in force—did not simply disappear. The rules may also reach Swiss companies supplying systems or outputs into the EU, depending on their role and use case.
“You cannot control market timing. If you are just too early to market, there is nothing you can do,” says LatticeFlow AI CEO Petar Tsankov. The strategic answer is not to rely on one compliance date. A strong proposition should solve a problem the customer cares about even if the deadline shifts: model performance, risk, documentation, vendor oversight or trust.
Risklick illustrates a different kind of timing. Founder Dr Poorya Amini initially struggled to convince pharmaceutical companies that clinical-trial protocol design could be improved. As industry interest in protocol quality increased, the company could position its solution within a problem that decision-makers had already begun discussing.
THE FOUNDER PLAYBOOK
- Maintain a regulatory calendar that separates laws already applicable, transitional rules, future obligations and proposals. Link each date to an official text.
- Translate each obligation into a concrete workflow, responsible owner and avoidable business risk.
- Stress-test demand: would customers still buy if the key regulatory deadline moved by 12 months?
4. Put market access and evidence on the same roadmap
In medical technology, a persuasive pilot is not a substitute for the applicable conformity and market-access requirements. Under the EU Medical Device Regulation (MDR), manufacturers follow a conformity-assessment route based on the device’s classification; many higher-risk devices require assessment by a notified body before CE marking. Switzerland has aligned substantial elements of its own medical-device regime, but cross-border obligations remain distinct.
Since the relevant Switzerland–EU mutual-recognition arrangements were not updated for the EU MDR in 2021, Swiss manufacturers have faced third-country requirements for EU market access. The March 2026 Switzerland–EU package included an amendment relating to mutual recognition, but signature alone does not establish that the revised rules are already operational; the applicable status and implementation must be checked before launch.
Market access extends beyond a certificate. macu4, for example, had to prepare US distributor landing pages with different legal content from its EU-facing pages. Claims, intended purpose, instructions, data handling and distributor responsibilities can all influence what is lawful and commercially feasible.
Nor is every pilot a commercial sale. Research and evaluation arrangements may be possible before a product is ready for routine deployment, but their permissibility depends on the device, intended use and applicable rules. Founders should obtain specialist advice rather than assume a letter of intent authorises clinical use.
THE FOUNDER PLAYBOOK
- Define intended purpose, device or software classification, target markets and required evidence before committing to a launch date.
- Plan regulatory work, quality management, data governance and sales enablement as one integrated project.
- Review country-specific marketing claims and distribution obligations before publishing or signing.
5. Win the people whose judgement travels
Regulated organisations rarely trust a vendor’s claims in isolation. Clinicians listen to clinicians; hospital leaders compare experiences with peers; procurement teams need defensible references. “Health care is a small crowd,” say heyPatient’s founders. That is why they invest in customer communities where hospitals can learn from each other.
This is also a lesson in pacing. Working with healthcare professionals and distribution partners, macu4 learned that simply providing more information could create friction. “Sometimes we are too fast for them. So we need to give them stepwise information and not overwhelm them with everything,” Lingg explains.
In large pharmaceutical companies, even identifying the right decision-maker can be difficult, Amini notes. A credible professional champion is therefore not just an advocate. They can help you understand how the buying organisation actually works.
THE FOUNDER PLAYBOOK
- Map professional champions, economic buyers, compliance owners and procurement stakeholders separately.
- Give each group the evidence it needs: clinical utility, implementation workflow, cost impact or legal assurance.
- Make early customers referenceable—subject to their consent and applicable confidentiality rules.
The regulated-market readiness test
Before calling an opportunity “qualified”, can you answer five questions: (1) Who will use the product? (2) Which specific budget pays? (3) Who can approve and sign? (4) Which purchasing process and evidence are required? (5) What is legally permitted at each stage, from pilot to routine use?
If one answer is missing, the deal may still be promising—but the sales forecast is not yet reliable. In regulated markets, the fastest path to growth often begins by discovering what would otherwise stop the sale.
Put this into practice
Use the Founders Hive template “Market & Customer Definition in 8 Steps”. In the ICP Card (Step 4), add the authorised signatory and the applicable procurement route alongside user, payer and decision-maker. In the Readiness Scorecard (Step 5), specify the reimbursement pathway or budget line, market-access prerequisites and evidence needed to proceed.
Founders Hive publishes this series as part of the Innosuisse Entrepreneurship Training programme. Founder quotations are drawn from interviews conducted for the series; quotations have been retained from the supplied article.
Sources
- Swiss intercantonal procurement thresholds 2026–2027 (official cantonal publication) — https://bl-api.webcloud7.ch/politik-und-behorden/direktionen/bau-und-umweltschutzdirektion/generalsekretariat/oeffentliche-beschaffungen/downloads/schwellenwerte_2026-2027.pdf
- Swiss federal procurement framework (BöB), thresholds and distinctions — https://www.astra.admin.ch/dam/astra/de/dokumente/abteilung_direktionsgeschaefteallgemein/bericht_zum_beschaffungswesen_astra_2024.pdf.download.pdf/Bericht%20zum%20Beschaffungswesen%20des%20ASTRA%202024.pdf
- EU AI Act consolidated regulation, as amended July 2026 — https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02024R1689-20260727
- European Commission: AI Act implementation timeline — https://digital-strategy.ec.europa.eu/en/policies/regulatory-framework-ai
- ZEW policy brief 26-12: start-ups and procurement — https://www.zew.de/en/publications/facilitating-access-for-innovative-start-ups-to-the-procurement-market-the-potential-of-criteria-based-contract-awards
- Swissmedic: mutual recognition agreements — https://www.swissmedic.ch/swissmedic/de/home/ueber-uns/internationale-zusammenarbeit/bilaterale-zusammenarbeit-mit-partnerbehoerden/mutual-recognition-agreements.html
- Swiss Confederation: Switzerland–EU package of agreements — https://www.europa.eda.admin.ch/de/botschaft-paket-schweiz-eu
- SwissDRG: tariff system — https://www.swissdrg.org/